Mironid, a Glasgow, UK-based biopharmaceutical company developing small molecule therapeutics, extended its Series A funding.
The round, which brought the total amount raised to date to £35M, was led by Roche Venture Fund with participation from existing investors Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, the University of Strathclyde, Scottish Enterprise and the European Investment Fund.
The company intends to use the funds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate.
Led by CEO Neil Wilkie, Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease. Its lead program is for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which is characterized by growth of fluid-filled cysts and is the most common hereditary kidney disorder, but has limited treatment options. Its small molecule LoAc® drug candidates directly target the abnormally high kidney cAMP levels that drive cyst formation.
FinSMEs
13/09/2023